Enzon Pharmaceuticals Inc  

(Public, NASDAQ:ENZN)   Watch this stock  
Find more results for ENZN
1.04
+0.06 (5.65%)
After Hours: 1.04 0.00 (0.00%)
Apr 23, 5:09PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 0.98 - 1.04
52 week 0.78 - 4.02
Open 0.99
Vol / Avg. 0.00/585,725.00
Mkt cap 45.86M
P/E 2.67
Div/yield 0.45
EPS 0.39
Shares 44.09M
Beta 0.97
Inst. own 68%
May 28, 2014
ENZON PHARMACEUTICALS INC Annual Shareholder Meeting - 10:00AM EDT - Add to calendar
May 5, 2014
Q1 2014 ENZON PHARMACEUTICALS INC Earnings Release (Estimated) Add to calendar
Mar 14, 2014
Q4 2013 ENZON PHARMACEUTICALS INC Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '13) 2013
Net profit margin 73.78% 52.62%
Operating margin 67.16% 52.65%
EBITD margin - 67.16%
Return on average assets 146.59% 17.54%
Return on average equity 175.57% 43.88%
Employees 43 -
CDP Score - -

Address

20 KINGSBRIDGE ROAD
PISCATAWAY, NJ 08854
United States - Map
+1-732-9804500 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Enzon Pharmaceuticals, Inc. (Enzon) is a biotechnology company. The Company´┐Żs drug development programs utilize two platforms: Customized PEGylation Linker Technology (Customized Linker Technology) and third-generation messenger ribonucleic acid (mRNA) antagonists utilizing the Locked Nucleic Acid (LNA) technology. The Company has four compounds in human clinical development, a PEGylated version of the active metabolite of the cancer drug, irinotecan, PEG-SN38, and mRNA antagonists Survivin and the Androgen Receptor (AR). In addition, it has mRNA antagonist targets in various stages of preclinical research. The Company receives royalty revenues from licensing arrangements with other companies related to sales of products developed using its Customized Linker Technology-PEGINTRON. It is also using LNA technology to develop mRNA antagonists against oncology targets.

Officers and directors

George W. Hebard III Interim Principal Executive Officer and Chief Operating Officer
Age: 40
Bio & Compensation  - Reuters
Richard L. Feinstein Principal Financial Officer, Vice President - Finance
Age: 70
Bio & Compensation  - Reuters
Andrew D Rackear J.D. Chief Compliance Officer, General Counsel, Secretary & Head of Human Resources
Age: 59
Bio & Compensation  - Reuters
Jonathan N. Christodoro Director
Age: 36
Bio & Compensation  - Reuters
Odysseas D. Kostas M.D. Director
Age: 36
Bio & Compensation  - Reuters
Jennifer McNealey Director
Bio & Compensation  - Reuters